You are here: Industry Insights > Theravance

News List

Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis drugs
August 24, 2021
Theravance Biopharma, Inc. today announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis.
J&J, Theravance's izencitinib fails Phase II ulcerative colitis trial firstwordpharma
August 24, 2021
Shares in Theravance Biopharma tumbled about 22% in after-hours trade on Monday after the company said izencitinib did not meet the primary endpoint of a Phase IIb trial of patients with ulcerative colitis (UC).
Theravance Biopharma Announces Proposed Public Offering of Ordinary Shares firstwordpharma
June 25, 2021
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma"), announced today that it intends to offer its ordinary shares in an underwritten public offering.
Theravance Biopharma Plans Upcoming Stock Sale; Shares Sink Nearly 10% in Extended Trading firstwordpharma
June 25, 2021
Shares of Theravance Biopharma were down almost 10% in after-hours trading on Thursday after the company disclosed plans for a public offering of its common stock, as reported by Fidelity.
Theravance, Mylan Expand YUPELRI® Development and Commercialization Agreement americanpharmaceuticalreview
June 20, 2019
Theravance Biopharma Ireland Limited and Mylan announced the expansion of the companies' current development and commercialization agreement for nebulized revefenacin to include China and certain adjacent territories.
Theravance and Mylan expand agreement for nebulised revefenacin pharmaceutical-technology
June 19, 2019
Theravance Biopharma Ireland and Mylan have expanded their existing development and commercialisation agreement for nebulised revefenacin.
FDA Approves Yupelri americanpharmaceuticalreview
November 13, 2018
FDA Approves Yupelri
Mylan and Theravance’s COPD treatment gets FDA approval expressbpd
November 10, 2018
Theravance Biopharma and partner Mylan won US regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.
Theravance Biopharma, Mylan Submit NDA for Revefenacin americanpharmaceuticacreview
November 14, 2017
The NDA is supported by the companies' Phase 3 program for revefenacin, which consisted of two replicate pivotal Phase 3 efficacy studies and a 12-month, open-label, active comparator safety study.
Theravance COPD drug clears safety study, setting up NDA fiercebiotech
July 21, 2017
Theravance Biopharma and Mylan are still on course to file for approval of their nebulized chronic obstructive pulmonary disease (COPD) therapy in the fourth quarter after posting 12-month safety data.